Home > Oncology > ASCO 2021 > Gastrointestinal Cancers > Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC

Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC

Presented By
Prof. Markus Moehler, Mainz University Clinic, Germany
Conference
ASCO 2021
Trial
Phase 3, CheckMate 649
The addition of nivolumab to chemotherapy demonstrated improved survival benefit along with an acceptable safety profile, while maintaining tolerability and quality of life in patients with gastric cancer/gastric-oesophageal junction cancer and oesophageal adenocarcinoma (GC/GEJC/EAC), additional data from CheckMate 649 showed. Standard chemotherapy for advanced GC/GEJC/EAC results in poor overall survival (median <1 year) [1]. Recently, the CheckMate 649 trial (NCT02872116) demonstrated a survival benefit of nivolumab/chemotherapy versus chemotherapy alone in patients with advanced GC/GEJC/EAC [2]. Prof. Markus Moehler (Mainz University Clinic, Germany) presented additional data [3]. CheckMate 649 enrolled 789 patients in the nivolumab/chemotherapy arm and 792 patients in the chemotherapy alone arm. At 12.1 months minimum follow-up, nivolumab/ch...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on